Rugang Zhang was poring over cellular debris in his Houston lab when he spotted the invisible culprit behind a lifetime of silent damage: R-loops, rogue tangles of DNA and RNA, slipping out of aging cells’ nuclei and setting off false alarms in the body’s immune system. What his team at The University of Texas MD Anderson Cancer Center uncovered isn’t just a new chapter in the biology of aging—it’s a potential roadmap to slowing one of the root drivers of chronic disease.
For years, scientists have known that persistent inflammation, often called “inflammaging,” fuels conditions like cancer, diabetes, and heart disease. But the precise trigger remained elusive. Now, Zhang’s study, published in Nature Aging, reveals that in senescent cells—those that have stopped dividing but refuse to die—R-loops are increasingly shuttled from the nucleus into the cytoplasm by two proteins: DDX1 and XPO1. Once outside, these R-loops latch onto floating DNA fragments, tricking the immune system into launching a constant, unwarranted inflammatory response, like a fire alarm stuck in the on position.
The breakthrough came when researchers blocked XPO1, the so-called “exit gate,” using KPT-330 (selinexor), an FDA-approved drug for multiple myeloma. In preclinical models, the treatment trapped R-loops inside the nucleus, halting the inflammatory cascade. The results were striking: inflammation markers dropped, liver fibrosis improved, fat accumulation reversed, muscle loss slowed, and, most remarkably, lifespan increased significantly. Because KPT-330 has already undergone human safety trials, the leap from lab to clinic could be shorter than usual.
Yet the team also discovered a delicate balance: this same inflammatory signal helps the immune system detect and destroy precancerous cells. Shutting it down completely could be risky. That’s why Zhang’s team is now eyeing DDX1, the protein that ferries R-loops to the exit, as a more precise target. Blocking DDX1 could silence the harmful noise of chronic inflammation without disabling the body’s early-warning system for cancer.
While questions remain—like why aging cells export more R-loops in the first place—this research opens a new frontier in treating not just individual diseases, but the biological aging process itself. For millions facing age-related decline, the possibility of a treatment that targets the root cause, not just the symptoms, feels like a quiet revolution unfolding in a Houston laboratory.